Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-335, Odalasvir, and Simeprevir in Japanese Patients with Chronic Hepatitis C
NCT02993250Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2016
- Primary completion
- May 2018
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of adafosbuvir, odalasvir, simeprevir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Started Dec 2016; status: completed.
02
Drugs
adafosbuvirodalasvirsimeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02993250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993250.